KR20200024185A - Pharmaceutical and food composition for treating or alleviating influenza a - Google Patents

Abstract

Disclosed is an antiviral agent which exhibits an alleviation effect against influenza A virus. The antiviral agent according to the present invention comprises maple syrup, Phllylostachys nigra, Coix lacryma-jobi, xylitol, vitamin C, manuka honey, Boswellia sacra, Commiphora abyssinica, and propolis in a powder, liquid or extract form.

Description

Antiviral agent for the treatment or alleviation of influenza A virus {{ARMAUTICAL AND FOOD COMPOSITION FOR TREATING OR ALLEVIATING INFLUENZA A}

The present invention relates to an antiviral agent, and more particularly, to an antiviral agent exhibiting a symptomatic improvement effect against influenza A virus.

How to stay ill and how to get over it is mostly the same. One way is to increase immunity to pathogenic microorganisms and combat pathogenic microorganisms. Pathogenic microorganisms include viruses, bacteria, fungi, acarus folliculorum and the like. Among these, viruses are not yet able to accurately identify the identity of modern medicine yet. The present inventors have speculated that many diseases in which modern medicine fails to provide a proper treatment are caused by infection of a virus, and the application of the antiviral agent according to the present invention to many patients has confirmed that this is true. Thus, the fight against viruses will play a key role in overcoming many diseases.

On the other hand, viruses are difficult to screen for pathogenicity. Even if a vaccine or a therapeutic drug is found, it is very difficult for the resistant virus to be expressed, and thus it is very difficult to continuously produce a therapeutic effect. In addition, the virus is parasitic in the cell of the host by the nature of the host when the host's immunity is strong lurks in the cell to avoid contact with the immune cells, and when the host's immunity is weakened, the virus finally comes out of the cell and exerts its pathogenicity. Therefore, unlike bacteria and fungi, even if the virus is infected, the pathological symptoms of the virus is not many due to the inactivity of the virus is difficult to determine whether the virus is pathogenic. Tuberculosis and leprosy have been mistaken for heredity in times of lack of information about bacteria. Although some diseases are viral diseases, they are mistaken for genetic diseases or family history due to the discovery of the virus or the pathogenicity of the virus.

Viruses are parasitic in living cells, small in size, and simple in structure, making them highly prone to mutations. Because viruses continue to appear in new varieties and variants, there are many more unknown types than known ones. Since the emergence of new or variant viruses is frequent and unpredictable, the development of vaccines is difficult. Antiviral agents, which are difficult to develop due to the appearance of frequent variants, are often difficult to continually exert.

Conventionally, antiviral agents have been developed and applied to different drugs for each type of virus. In the case of viral diseases such as avian influenza, severe acute respiratory syndrome, novel influenza, and Middle East respiratory syndrome coronavirus, vaccines and therapeutics that have specific effects on individual diseases are being developed. However, these vaccines and therapeutic agents do not work against variants or newly emerged viruses.

Therefore, there is a need to develop foods that can improve or cure symptoms against various kinds of viral diseases and diseases suspected of viral diseases.

US Patent Publication No. 2004/0091555 A1 discloses a preparation method of a medicinal herb extract having an antiviral effect against hepatitis B virus, and a food antiviral agent containing the extract. However, the extract is only effective for the hepatitis B virus, and does not show effect on other types of viral diseases or diseases suspected of viral diseases.

Patent Registration Publication No. 10-1627065 (Registration Date: 2016.05.27)

An object of the present invention to provide an antiviral agent that can improve the symptoms of influenza A virus diseases.

The above object of the present invention can be achieved by an antiviral agent comprising maple syrup, bamboo, uiyiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis in powder, liquid or extract form.

The antiviral agent according to the present invention may be mixed with powder of maple syrup, bamboo, uiyiin, xylitol, vitamin C, frankincense extract, myrrh, and extract of propolis, manuka honey may be further mixed into pills or granules.

The antiviral agent according to the present invention may include an extract extracted from a mixture of maple syrup, bamboo, uiyiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis as an active ingredient.

The antiviral agent according to the present invention, hepatitis B, hepatitis C, herpes zoster, adenovirus, rhinovirus, influenza, avian influenza, severe acute respiratory syndrome, novel influenza, Middle East respiratoryza It can also improve symptoms of known viral diseases such as syndrome coronavirus and cold virus. In addition, the antiviral agent according to the present invention has the effect of ameliorating or healing the symptoms of the following diseases suspected of being a viral disease.

1) It is presumed that the virus is infected when the pain is continuously and repeatedly induced in the same area, such as fibromyalgia, chronic musculoskeletal pain, and chronic fascia pain. The antiviral agent according to the present invention has an effect of improving or healing a condition in which pain is continuously and repeatedly induced in the same site as in the case of fibromyalgia, chronic musculoskeletal pain, chronic fascia pain, and the like.

2) Persistent and repetitive lesions in the same area, such as atopic dermatitis and allergic rhinitis, are presumed to be virus-infected. Antiviral agent according to the present invention, such as atopic dermatitis (atopic dermatitis), allergic rhinitis, etc., has the effect of improving or healing the symptoms causing persistent and repetitive lesions in the same site.

3) Most diseases belonging to allergy or autoimmune diseases are presumed to be viral infections. The antiviral agent according to the present invention has the effect of improving or healing most diseases or conditions belonging to allergy or autoimmune diseases.

4) In case of inflammation, such as psoriasis, the color of the inflammation area is a little red, but it is not easily purged and the inflammation is continuously maintained. The antiviral agent according to the present invention has an effect of improving or healing the symptoms of repetitive severity while maintaining inflammation, but the color of the inflammatory site is slightly red but not easily purged and continuously maintained.

5) Repeated and persistent chronic inflammation of mucous membranes such as eyes, nose, mouth, gums (periodontal period), neck, stomach, small intestine, large intestine, bladder, and female genitals is thought to be a viral infection. The antiviral agent according to the present invention may improve chronic inflammation that occurs repeatedly and continuously in the externally exposed mucosal areas such as eyes, nose, mouth, gum (periodontal period), neck, stomach, small intestine, large intestine, bladder, female genitalia, or It has a healing effect.

6) Some adult diseases or life style diseases, such as diabetes, hypertension, etc., are presumed to be caused by infection of the virus at the relevant site. The antiviral agent according to the present invention is effective in ameliorating or healing symptoms such as adult diseases or life style diseases such as diabetes, hypertension, etc. caused by a virus.

7) Genetic diseases, such as Down's syndrome, Cri du chat syndrome, and Muscular Dystrophy, are also considered to be viral diseases of the central nervous system. The antiviral agent according to the present invention has the effect of ameliorating or healing the symptoms of diseases discussed as genetic diseases such as Down's syndrome, Cri du chat syndrome, Muscular Dystrophy.

8) One of the causes of central nervous system diseases, such as developmental disorders, brain lesion disorders, and dementia, is also believed to be caused by the virus in the relevant area. The antiviral agent according to the present invention has the effect of improving or healing the symptoms of central nervous system diseases such as developmental disorder, brain lesion disorder, dementia and the like.

The antiviral agent according to the present invention includes maple syrup, bamboo, uiyiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis in powder, liquid or extract form.

The antiviral agent according to the present invention can be made into pills or granules by further mixing manuka honey, maple syrup, and mortality with a mixed powder of yiyiin, xylitol, vitamin C, frankincense extract, myrrh, and extract of propolis.

The antiviral agent according to the present invention may include an extract extracted from a mixture of maple syrup, bamboo, uiyiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis as an active ingredient.

The composition components and the composition ratio between the components of the present invention are as follows.

1) 1-30% by weight of the maple syrup collected from the sap of the Canadian maple;

2) 1 to 30% by weight of bamboo salt (natural bamboo flavor), a sap of bamboo that is evaporated by strong heat in the process of making charcoal from bamboo;

3) 5 to 60% by weight of uiyiin, a food ingredient known to have antibacterial function (based on the total weight, as follows);

4) 10 to 40% by weight of xylitol, a food material that is also known to have antibacterial function;

5) 1 to 20% by weight of vitamin C, a nutrient known as antioxidant;

6) 1-20% by weight of manuka honey, a food known to have an antibacterial active substance;

7) 1 to 20% by weight of frankincense, a food known to have detoxification function;

8) 1 to 20% by weight of myrrh, a food known to have a function of removing blood;

9) 0.1 ~ 10% by weight of propolis extracted from beehives and used as food ingredients.

Addition of less than 5% by weight of Euiin is insignificant antiviral effect by the righteous, and adding more than 60% by weight of Euiin is less effective anti-varus effect by the other, while adding antiviral function by other materials Difficult to provide efficacy against various types of viruses.

If the maple syrup is added less than 1% by weight, the antiviral effect of maple syrup is insignificant. If the maple syrup is added more than 30% by weight, the antivirus effect is increased by the maple syrup, while the antiviral effect of other materials is reduced. It's hard to add features so it's hard to be effective against different kinds of viruses.

The addition of less than 1% by weight of the anti-viral effect of the death is insignificant, and the addition of more than 30% by weight of the mortality increases the anti-viral effect by the death, while adding the anti-viral function by other materials Difficult to provide efficacy against various types of viruses.

When xylitol is added in less than 10% by weight, the antiviral effect by xylitol is insignificant, and when xylitol is added in excess of 40% by weight, the antivirus effect is increased by xylitol while adding antiviral function by other materials. Difficult to provide efficacy against various types of viruses.

If the vitamin C is added in less than 1% by weight, the antiviral effect of vitamin C is insignificant. If the vitamin C is added in excess of 20% by weight, the antiviral effect is increased by vitamin C, while the antiviral effect of other materials is reduced. It's hard to add features so it's hard to be effective against different kinds of viruses.

When Manuka honey is added in less than 1% by weight, the antiviral effect of Manuka honey is minimal, and when Manuka honey is added in excess of 20% by weight, the antivirus effect is increased by Manuka honey. It's hard to add features so it's hard to be effective against different kinds of viruses.

If the amount of frankincense is less than 1% by weight, the antiviral effect of frankincense is insignificant. If the amount of frankincense exceeds 20% by weight, the antiviral effect is increased by the frankincense, while the antiviral function is added by other materials. Difficult to provide efficacy against various types of viruses.

If the amount of myrrh is less than 1% by weight, the antiviral effect of the myrrh is insignificant. If the amount of the myrrh exceeds 20% by weight, the antiviral effect is increased by the myrrh, while it is difficult to add antiviral function by other materials It is difficult to have efficacy against a variety of viruses.

If the propolis is added in less than 0.1% by weight, the antiviral effect of the propolis is insignificant. If the propolis is added in excess of 10% by weight, the antivirus effect by the propolis is small, while the antiviral function of other materials It is difficult to add it, so it is difficult to have efficacy against various kinds of viruses.

The antiviral agent according to the present invention may further be mixed with manuka honey and propolis in a mixed powder of maple syrup, bamboo, uiyiin, xylitol, vitamin C, frankincense, and myrrh to make an oral pill, granule, or powder.

The antiviral agent according to the present invention may further contain Manuka honey in a mixed powder of maple syrup, bamboo, uiyiin, xylitol, vitamin C, frankincense extract, myrrh, and extract of propolis, as an oral pill, granule, or powder. I can make it.

The antiviral agent according to the present invention comprises maple syrup, bamboo, uiyiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis by mixing water, or ethanol, or an extract extracted with water and ethanol as an active ingredient. It may be made as an oral tablet, granule, powder, or liquid.

Maple syrup is a collection of concentrated sap from Canadian maple trees and is currently used as a substitute for sugar.

Bamboo power (natural bamboo flavor), In the process of making charcoal from bamboo, the sap of bamboo, which is evaporated by strong heat, is sweet and tastes cold. In Chinese medicine, it is known to act on the heart and stomach, and to reduce heat and cut phlegm.

The Ui-in is a dried seed of Yulmu, a gramineae species. Yulmu is planted in various parts of Korea.

Xylitol is pentose (C ₅ H ₁₂ O _5. Molecular weight 152.15) extracted from birch bark and sap.

Vitamin C is an antioxidant that protects the body from free radicals and prevents cancer, arteriosclerosis and rheumatism. It also strengthens the immune system.

Manuka honey is a honey bee collected by honey from the flowers of a Manuka tree native to New Zealand.

Frankincense is a condensation-dried resin that exudes from the trunk and bark of frankincense water, a tropical plant belonging to the Olive family.

Myrrh is the extract of the succulents exuded from the trunk of the myrrh (Mirara), a small arborescent tree in the Burseraceae, and from the upper mouth of the skin. The oily resin (乳狀 樹脂) is dried to form a reddish brown mass.

Propolis is made by bees collecting resin from trees, grasses and flowers and mixing their saliva and secretions.

Among the components of the antiviral agent according to the present invention, maple syrup, bamboo, uiyiin, xylitol, manuka honey, frankincense, myrrh and propolis are those derived from natural life, and their individual antiviral effects are insignificant, In case of various viral diseases, there is a large synergistic effect, unexpected from the individual effects.

One of the characteristics of viral diseases is that they occur intensively in areas with frequent contact with foreign substances such as skin and mucous membranes. Since most viruses are infected by contact, they are frequently infected with skin or mucous membranes where they are frequently in contact with foreign objects or objects. Viruses are difficult to penetrate directly into healthy skin and are susceptible to infection through sites of infection, inflamed areas, or skin injuries of the acarus folliculorum. The virus easily penetrates the mucosa and can infect the inner wall of the nose, bronchial wall, lining of the mouth, stomach wall, small wall of the small intestine, inner wall of the large intestine, inner wall of the anus, inner wall of the vagina, inner wall of the uterus, cornea and conjunctiva of the eye. Viruses that prefer specific cells can only infect certain sites. Viruses that are friendly to certain cells, such as the hepatitis B virus, only infect certain sites.

Another feature of viral diseases is that the symptoms do not heal cleanly and the symptoms repeat, depending on the state of health. Normal immunity survives only within the cell and does not cause any special lesions. Then, weakened immunity infects surrounding cells and causes inherent lesions. As such, viral diseases are not clear and the symptoms are repeated and persist according to the immunity.

Another feature of viral diseases is that the causal virus is difficult to find. Bacterial diseases are easy to find causative bacteria. However, if the pathogenic and viral diseases that cause chronic diseases, usually hidden in the cells do not cause inflammation, but weak immunity causes weak inflammation or sensitive cell reactivity. The causative agent of certain diseases can be found continuously in the same area of a patient with weak immunity. Therefore, the virus can be determined as the virus causing the specific disease. However, the virus can also be found in similar sites in immunized healthy individuals who have never had a particular disease. As a result, the virus can be classified as a virus that does not conclude as a virus causing a specific disease and is not pathogenic. On the other hand, assuming that the disease having the above characteristics as a viral disease, and applying the antiviral agent according to the present invention, it was confirmed that the symptoms are improved or cured.

Known viral diseases include influenza, viral hepatitis, viral enteritis, herpes zoster, viral conjunctivitis, polio, infantile paralysis, and AIDS. , Viral brain lesion disorders, measles, mumps, etc. Even in these viral diseases, many antiviral agents have not yet been developed.

Diseases having all the characteristics of the above-described viral diseases include the following.

Autoimmune diseases such as vitiligo; Allergy diseases such as atopic dermatitis; Chronic pain diseases of the musculoskeletal system; Sickness or development of infants; Lifestyle diseases such as hypertension and diabetes; Some infertility; Central nervous system diseases such as developmental disorders, brain lesions, and the like; Diseases known as genetic diseases such as Down's syndrome, Cri du chat syndrome, Muscular Dystrophy, etc .; Dementia.

These diseases are all believed to be viral diseases or diseases associated with viral infections.

Autoimmune diseases, which are not exactly the cause of the disease, are inflammatory reactions due to the reaction of immune cells by a substance in the body, vitiligo, rheumatism, Crohn's disease, lupus, pemphigus ( pemphigus). These diseases mean a condition in which the body continues to be inflamed due to an immune response, which is named as an autoimmune disease because bacteria or fungi are not found and the cause of inflammation cannot be found. Autoimmune diseases are diseases that show all the typical characteristics of the viral diseases described above. The present inventors speculate that autoimmune disease is not a disease in which an immune response is caused by inflammation by a substance in the body but is a viral infection disease in which an immune response occurs at an infection site due to a viral infection.

Allergy and autoimmune diseases are the same disease in terms of immune hyperactivity, and most of the organ-specific autoimmune diseases are included in type II allergy, so it is difficult to find a boundary. In fact, allergy is clearly identified as the substance of the allergy (allergy), the unknown yet is the autoimmune disease. However, the inventors of the present invention, most allergic (allergy), including atopic dermatitis, a relatively weak pathogenic virus enters the cell to make the state of the cell sensitive, and another inflammatory substance antigen to stimulate the cell to trigger an immune response Guess it's a viral disease.

When muscles or ligaments are damaged, such as fibromyalgia and chronic musculoskeletal pain, immunity decreases and the virus gets worse before the damaged cells recover completely. In addition, due to the nature of viral inflammation, the inflammation does not heal cleanly and the symptoms continue to repeat. In this case, it has been confirmed through many clinical studies that the symptoms are reliably improved by combating the virus by the antiviral agent according to the present invention and appropriately strengthening the affected part. In addition, it was confirmed through clinical trials that the virus or ligament was damaged by external shock or excessive exercise, and it was a viral infection even if it did not heal cleanly and caused repeated and persistent symptoms.

The present inventors assume that the specific disease or underdevelopment of infants is also a viral disease. Virus infections in young children can interfere with growth by causing a variety of symptoms, including recurrent cold symptoms, enlarged tonsils, poor growth, weakness, loss of appetite, and poor digestion. In this case, the fight against the virus keeps the sick child healthy and helps normal growth.

The inventors assume that hypertension and diabetes are also diseases associated with the virus. The cause of type 1 diabetes is known to be the destruction of the pancreas by antibodies caused by viral infections such as mumps and rubella. However, in the clinical cases of type 1 diabetic patients, the antiviral agent according to the present invention has been identified as a number of cases of reducing insulin. In addition, patients with type 2 diabetes or hypertension who are not well controlled often experience clinically stable and controlled treatment with only the antiviral agent according to the present invention, and among diabetes or hypertension patients, the virus is a direct cause or secondary symptoms. It is assumed that it will often act as a cause of deterioration.

We assume that infertility is a disease associated with a virus. As mentioned earlier, mucous membranes are areas that are susceptible to viral infection. Virus infections can occur frequently on the genital mucosa, and when these infections become inflamed, it can cause infertility. Therefore, even in infertile women, it is necessary to eradicate the virus while taking the antiviral agent according to the present invention. Many cases have been confirmed through clinical cases in which the loss of the virus improves physical fitness and pregnancy.

The present inventors assume that central nervous system diseases such as developmental disorders and brain lesions are also diseases associated with viruses. Developmental disorder (developmental disorder) is a disease that the inventors suspected as a viral central nervous system disease through a number of clinical cases and still a clinical case that is still suspected to be a viral central nervous system disease. Although it is not yet known in modern medicine, diseases such as developmental disorders and brain lesions are assumed to be central nervous system diseases caused by viruses, and the case of improvement of neuronal regeneration based on antiviral drugs according to the present invention. I have experienced it many times. In addition, as the virus is eradicated, the intelligence increases and symptoms improve from time to time.

The present inventors speculate that diseases such as Down's syndrome, Cri du chat syndrome, and Muscular Dystrophy, which are regarded as genetic diseases in modern medicine, may also be diseases related to viruses. Many neurological disorders, such as Down's syndrome, Cri du chat syndrome, Muscular Dystrophy, etc., or unknown or hereditary diseases, are based on the use of antiviral agents according to the present invention. There have been several times when the process has improved. This repeated experience suggests that many of the diseases discussed as genetic diseases are due to viral infections.

We assume that dementia is also a disease associated with a virus. The cause of developmental disorders, brain lesions, etc. is assumed to be the central nervous system disease caused by the virus, and dementia may be the same cause because symptoms are improved when the virus is eradicated. The antiviral agent according to the present invention is expected to play a large role in the prevention and treatment of dementia.

Thus, based on the research and clinical experience so far, it is speculated that many diseases that are not yet identified as causes and many diseases considered to be genetic diseases belong to viral diseases.

[Example]

1) The antiviral extract according to the present invention was prepared several times in the following amounts for in-vitro testing for viral diseases.

Maple Syrup 180g, Bamboo 220g, Uiin Powder 320g, Manuka Honey 120g, Xylitol Powder 270g, Vitamin C Powder 120g, Boswellia 50g, Myrrh Powder 100g, Propolis 20g, a mixture of 50% ethanol and 1:30 (Mix 1: 50% ethanol was mixed at a weight ratio of 30) and extracted in a pressure extractor for 3 to 12 hours at a temperature of 100 ~ 120 ℃ to make an antiviral extract.

2) In order to confirm clinical trials and efficacy of viral diseases, antiviral drug rings according to the present invention were prepared several times at the following ratios.

Maple syrup 10%, mortality 12%, Uyiin powder 20%, xylitol powder 22%, vitamin C powder 7%, frankincense extract powder 5%, myrrh powder 10%, propolis extract powder 2% Made of a mixed powder, and further mixed with 12% by weight of Manuka honey to make a small lyophilized ring having a diameter of 3.8mm, and then packaged in units of 4.8g. To obtain frankincense extract and propolis extract, mix frankincense and propolis with 50% ethanol at a weight ratio of 1:30 (frankincense or propolis 1: 50% ethanol 30), respectively, and then press the pressure extractor at 100-120 ° C. After extracting for 3 to 12 hours, ethanol was evaporated for a suitable time in order to remove the components of ethanol, and the residue was dried and powdered.

Antiviral test

Using Influenza A virus (H1N1: Influenza A), Human Rhinovirus A (HRV), Transmissible gastroenteritis virus (TGEV) and Encephalomyocarditis virus (EMCV: Brain Myocarditis Virus) as test viruses, The test for measuring the antiviral ability of the antiviral agent according to the present invention was conducted according to ASTM E1052-11.

1.1. Culture of Host Cells

MDCK, HeLa, ST, Vero cells were cultured at 5% CO ₂ concentration (36 ± 2) ℃ conditions using cell culture medium.

1.2. Cultivation of virus

1.2.1. Influenza A culture

MDCK cells monolayered in 75-cm²flask were washed with PBS and then inoculated with 3 mL of Influenza A dilution. After infecting the virus for 60 to 90 minutes at 5% CO ₂ concentration and (33 ± 2) ℃, virus culture medium is added for 5 ~ 7 days until more than 90% of host cells show cell lesions. Incubated. Thereafter, the culture supernatant was centrifuged at 2000 rpm for 10 minutes, and the supernatant was filtered through 0.2 filter to isolate viruses.

1.2.2. HRV culture

HeLa cells cultured in a 75-cm² flask were washed with PBS, and then inoculated with 3 mL of the HRV dilution. After infecting the virus at 5% CO ₂ concentration (33 ± 2) ℃ for 60 ~ 90 minutes, virus culture medium was added and cultured for 3-7 days until more than 90% of host cells showed cell lesion. . Thereafter, the culture supernatant was centrifuged at 2000 rpm for 10 minutes, and the supernatant was filtered through 0.2 filter to isolate viruses.

1.2.3. TGEV culture

After monolayer cultured ST cells in a 75-cm² flask was washed with PBS, EMEM (w / o TPCK-treated trypsin) was added to 5% CO₂, (36 ± 2) ℃ 3 hours. Thereafter, 3 mL of TGEV dilutions diluted with virus culture medium (w / TPCK-treated trypsin) were inoculated. After infecting the virus for 60 to 90 minutes at 5% CO ₂ concentration (33 ± 2) ℃ conditions, the virus was incubated for 3 to 5 days until more than 90% of the host cells showed cell lesions by adding a virus culture medium. . Thereafter, the culture supernatant was centrifuged at 2000 rpm for 10 minutes, and the supernatant was filtered through 0.2 filter to isolate viruses.

1.2.4. EMCV culture

Vero cells monolayered in 75-cm² flasks were washed with PBS and inoculated with 3 mL of EMCV dilution. After infecting the virus at 5% CO ₂ concentration (36 ± 2) ℃ for 60 ~ 90 minutes, virus culture medium was added and cultured for 1 ~ 4 days until more than 90% of host cells showed cell lesion. . Thereafter, the culture supernatant was centrifuged at 2000 rpm for 10 minutes, and the supernatant was filtered through 0.2 filter to isolate viruses.

1.3. Antiviral test

1.3.1. Cytotoxicity Test

The virus culture medium was mixed at a ratio of 1: 9 in the test solution (90% test solution), and then diluted 10 times in the virus culture medium. The diluted test solution was treated with host cells at (36 ± 1) ℃ for 30 to 60 minutes, and then the cytotoxicity was visually observed through a microscope.

1.3.2. Cell culture control

The host cells were treated with virus culture media and used as cell culture controls.

1.3.3. Virus control

Test viruses were mixed in virus culture medium at a ratio of 1: 9 and treated at (22 ± 2) ° C. for 1 hour. The mixed solution was treated in the same manner as in the neutralization method of the virus test group (1.3.4.), And then diluted 10 times in the virus culture medium, and each diluted solution was inoculated into the host cells.

1.3.4. Virus test group

Test virus was mixed in the test solution at a ratio of 1: 9 and treated at (22 ± 2) ° C. for 1 hour. The preliminary test confirmed that the test solution induced cytotoxicity. The test solution was neutralized using a gel filtration column according to ASTM E1482-12. Immediately thereafter, 10-fold step dilution in virus culture medium was carried out, and each dilution was infected with host cells.

1.4. Verification test

1.4.1. Sub-cytotoxicity

After treatment with host cells for 30 minutes at the highest concentration of test solution that did not show cytotoxicity, the cell monolayer was washed with PBS and inoculated with the virus. Then 5% CO ₂ concentration, (33 ± 2) ℃ conditions (Influenza, HRV) or (36 ± 2) ℃ conditions (TGEV, EMCV) with 60 to infect 90 minutes virus and 5% CO ₂ concentration (33 Incubated for 3 ~ 10 days under ± 2) ℃ (Influenza, HRV) or (36 ± 2) ℃ (TGEV, EMCV)

1.4.2. Neutralization test

The neutralized test solution and virus were mixed in the same amount and reacted for 10 to 20 minutes, and then inoculated into host cells. Then 5% CO ₂ concentration, (33 ± 2) ℃ conditions (Influenza, HRV) or (36 ± 2) ℃ conditions (TGEV, EMCV) with 60 to infect 90 minutes virus and 5% CO ₂ concentration (33 Incubated for 3 ~ 10 days under ± 2) ℃ (Influenza, HRV) or (36 ± 2) ℃ (TGEV, EMCV)

1.5. Virus recovery

Dilute each solution by 10-fold step and dilute each step with 8 wells of 100 cells in 100 well prepared cells in 96 well plate, 5% CO ₂ concentration, (33 ± 2) ℃ condition (Influenza, HRV) Or (36 ± 2) ℃ (TGEV, EMCV) conditions were incubated for 3 to 10 days.

1.5.2. Dyeing condition

Staining reagents of 25% Methyl alcohol (v / v) and 0.5% crystal violet (w / v) were treated to the cells and stained for 10 minutes at (22 ± 2) ° C.

1.5.3. Observe the results

The number of wells stained with crystal violet was counted and the titer was calculated by Spearman-Karber method. Virus titers were calculated according to 1.6.1. Equation 1, and the reduction rate was determined according to 1.6.2.

1.6. Calculate the result

1.6.1. Virus titer calculation

[Virus titer formula]

L = X _0- (d / 2) + dx Σ (r _i / n _i )

L: Log ₁₀ TCID ₅₀ titer

X ₀ : Log ₁₀ of the reciprocal of the lowest dilution at which all test inocula are positive

d: Log ₁₀ of the dilution factor (that is, the difference between the log dilution intervals)

n _i : Number of test inocula used at each individual dilution

r _i : Number of positive test inocula (out of n _i )

Σ (r _i / n _i ): Sum of the proportion tests beginning at the lowest dilution showing 100% positive result

1.6.2. Calculation of Log reduction (LR)

[Log reduction formula]

LR = ML _U -ML _T

ML _U = Mean of the titers recovered from the virus control specimen (untreated)

ML _T = Mean of the titers recovered from virucidal test specimen (treated)

However, the log value should be written up to 2 decimal places.

1.7. Exam establishment condition

1.7.1. Cytotoxicity Test

No cytotoxicity of the host cell by the test solution should be observed. If the test solution directly causes cytotoxicity, it should be neutralized using a gel-filteration column.

1.7.2. Subcellular Toxicity Test

Although cytotoxicity by the test solution is not observed by visual observation, the test solution should be checked for subcellular toxicity because the test solution can increase or decrease the viral infectivity of the cells. When viral titers were (45 ± 5)% lower than the control group, the corresponding dilution factor was excluded from the reduction rate calculation.

1.7.3. Neutralization test

After the reaction between the test solution and the virus, the test solution should be neutralized and then neutralized. If the recovery of the virus is lower than (80 ± 5)% compared to the control group, since the neutralization was not sufficient, the appropriate neutralization step should be performed using a method such as gel-filteration column.

2. Results

2.1. Cytotoxicity of Test Solution

After the virus culture medium was mixed with the test solution at a ratio of 1: 9 (90% test solution), it was confirmed that cytotoxicity was induced in all host cells. As a result, it was confirmed that gel was produced according to ASTM E1482-12. The test solution was neutralized using filtration columns and used for the test. The neutralized test solution was observed for cytotoxicity up to 90% concentration (Table 1).

Cytotoxicity Test Results
Three Po Su

Maximum dilution factor without toxicity (test solution concentration) MDCK cells 10 ^-2 (9%) Hela cells 10 ^-2 (9%) ST cells 10 ^-2 (9%) Vero cells 10 ^-2 (9%)

2.2. Antiviral test result

The antiviral test results are shown in Table 1 and Table 2 below.

Antiviral test result (L) (unit: log ₁₀ TCID ₅₀ / mL)
            virus

  Virus control (after 1 hour)
         Test group (after 1 hour)
          Influenza a

             5.63
           〈2.50
          HRV
             7.88
             3.25
          TGEV

             6.75
             4.88
          EMCV

             8.63
             8.50

Virus Reduction Rate (LR)
            virus

                            LR
          Influenza a

                          〉 3.13

          HRV
                            4.63

          TGEV

                            1.87

          EMCV

                            0.13

If LR (Log reduction) is 1 or more, the percentage of virus reduction (% redution) is 90% or more. If LR (Log reduction) is 2 or more, the percentage of virus reduction (% redution) is 99% or more, and LR (Log reduction) is If it is 3 or more, the percentage of virus reduction (% redution) is 99.9% or more. If the LR (Log reduction) is 4 or more, the percentage of virus reduction (% redution) is more than 99.99%. If the LR (Log reduction) is 5 or more, the percentage of virus reduction. (% redution) is over 99.999% As a result of the test, it can be seen that there was a significant virus reduction rate for all kinds of test viruses, and in some cases, the percentage of virus reduction was 99.9% or more.

Subcellular toxicity test results and neutralization test results are shown in Table 4 and Table 5 below.

Subcellular toxicity test results (unit: log ₁₀ TCID ₅₀ / mL)
       virus

        Control
        Test group
        Result determination
     Influenza a

         5.63
         5.38
Lack of Interference
        HRV

         7.50
         7.13
Lack of Interference
        TGEV

         6.75
         6.50
Lack of Interference
        EMCV

         8.38
         8.38
Lack of Interference

Neutralization test results (Unit: log ₁₀ TCID ₅₀ / mL)
       virus

        Control
        Test group
        Result determination
     Influenza a

         5.50
         5.13
Successful neutralization
        HRV

         7.13
         6.88
Successful neutralization
        TGEV

         6.63
         6.38
Successful neutralization
        EMCV

         8.50
         8.75
Successful neutralization

2.2.1 Validity of Influenza A Antiviral Test

The titer of the virus control was 5.63 log ₁₀ TCID ₅₀ / mL and the test group was <2.50 log ₁₀ TCID ₅₀ / mL (Table 2).

No titer was observed in the cell culture control, no cytotoxicity and subcytotoxicity of the test solution (9%), and the neutralization of the sample was confirmed in the neutralization control, demonstrating the effectiveness of this test (Table 4, Table). 5).

2.2.2 Effectiveness of the HRV Antiviral Test

The titer of the virus control was 7.88 log ₁₀ TCID ₅₀ / mL and the test group was 3.25 log ₁₀ TCID ₅₀ / mL (Table 2).

No titer was observed in the cell culture control, no cytotoxicity and subcytotoxicity of the test solution (9%), and the neutralization of the sample was confirmed in the neutralizing control, demonstrating the effectiveness of this test (Table 4, Table). 5).

2.2.3. Effectiveness of the TGEV Antiviral Test

The titer of the virus control was 6.75 log ₁₀ TCID ₅₀ / mL and the test group was 4.88 log ₁₀ TCID ₅₀ / mL (Table 2).

No titer was observed in the cell culture control, no cytotoxicity and subcytotoxicity of the test solution (9%), and the neutralization of the sample was confirmed in the neutralization control, demonstrating the effectiveness of this test (Table 4, Table). 5).

2.2.4. Effectiveness of EMCV Antiviral Test

The titer of the virus control was 8.63 log ₁₀ TCID ₅₀ / mL and the test group was 8.50 log ₁₀ TCID ₅₀ / mL (Table 2).

No titer was observed in the cell culture control, no cytotoxicity and subcytotoxicity of the test solution (9%), and the neutralization of the sample was confirmed in the neutralization control, demonstrating the effectiveness of this test (Table 4, Table). 5).

3. Conclusion

The virus log reduction of Influenza A, HRV, TGEV and EMCV for the antiviral test solution of the present invention under these test conditions was found to be> 3.13, 4.63, 1.87, 0.13, respectively (Table 3). Therefore, the present invention confirmed that there is antiviral activity against these viruses.

Clinical Trial

Measures of Effect on Hepatitis B

Seven male and three female hepatitis B patients with a GOT in the range of 50 to 60 U / ml were dosed with an antiviral agent according to the present invention for two months with tids for 3 months and GOT measurement. Except for the remaining 9, all the GOT measurement results of the normal range of 32 ~ 38U / ml was obtained.

<Measurement of effects on influenza A virus>

Four patients with type A flu complaining of high fever, chills, headache, and muscle aches were treated with three antiviral agents of t.i.d. for 5 days. After 3 days of taking the body temperature of three people returned to normal body temperature, fever, chills, muscle pain disappeared, and after 5 days of intermittent mild fever, fatigue, cough, sore throat was confirmed to improve to the near normal.

<Measurement of effects on rhinoviruses>

Five women and five men with a nasal cold (rhinovirus infection) were given an antiviral agent according to the present invention, each of which was taken with t.i.d for 5 days. After 5 days, nasal as well as nasal congestion completely disappeared in 4 women and 3 men and the runny nose was significantly relieved in the remaining 3 patients.

<Measurement of effects on adenovirus>

Three females and three males of Mokgigi (Adenovirus infection) were given two doses of the antiviral agent according to the present invention, b.i.d, for 4 days. After 4 days, three patients disappeared, and the other three patients remarkably alleviated the symptoms of neck sickness including neck pain.

<Measure effect on shingles>

Three patients who were diagnosed with shingles who had passed for more than 1 year (hereinafter referred to as long-term treatment group) and five patients who had been diagnosed with shingles less than one month (short-term patient group) Two packets of antiviral agent according to the present invention were taken as tids for 2 months, and for the short-term treatment group, one packet was taken as bid for 1 month. In the long-term group of patients, shingles disappeared completely after the 2 months of treatment and the pain disappeared in 2 patients. In the short-term treatment group, shingles were no longer observed with pain disappearance in 4 patients after 1 month of treatment.

<Measure effect on psoriasis>

Three male patients and four female patients who had not been treated for more than one year after being diagnosed with psoriasis were given one dose of the antiviral agent according to the present invention as tids for 4 months and observed after 4 months. It was. Four months later, no seizure or erythema was visually observed in two male and two female patients. In the remaining patients, the extent of the sulcus and erythema was reduced to less than one-third of the pre-dose.

<Measurement of effects on atopic dermatitis>

In five patients with atopic dermatitis with pruritus in the arm and five patients with atopic dermatitis with pruritus in the leg, two doses of the antiviral agent according to the present invention were taken as tids for the first month. One month after and three months after the addition of each dose of tid to take additional doses, the state was observed. Among the 10 patients after the first month of use, pruritus disappeared in 9 patients and inflammation was alleviated. After three months of additional dosing, inflammation was no longer observed in four patients, and in three patients the extent of inflammation was reduced to less than one-quarter compared to pre-dose. There was no patient with pruritus remaining after 3 months of supplementation.

<Measurement of effects on cervical myofascial pain syndrome)

Ten patients with cervical fascia pain who feel neck pain even without movement were selected, and five patients (M1-M5) were given a pill according to <Example> of the present invention once per 28 days, 1 packet three times a day, For the remaining 5 patients (m1-m5), the effect of Tylenol 650mg 8-hour sustained-release medicine, which is commonly prescribed for cervical fascia pain syndrome, was taken three times a day for 1 day for 28 days. .

After taking 28 days, pain was not felt even when moving, 5 points, pain was not felt when not moving, but pain was felt when moving, 3 points were given, and pain was felt even when not moving.

The measurement results were shown in Table 6 below.

EXAMPLES Taking Patients

<Comparative example> Taking patient

M1

M2
M3
M4
M5

m1
m2
m3
m4
m5
3

3
One
5
3
3
One
3
One
3

In the above measurement results, it can be seen that the pain improvement degree of the patient taking the pill according to the embodiment of the present invention is superior to the pain improvement degree of the patient taking the pill according to the comparative example.

Measurement of effect on chronic plantar fasciitis

Ten patients with chronic plantar fasciitis suffering from footpadak without walking were selected, and five patients (M1-M5) were to take the pill according to the <Example> of the present invention twice a day for 2 days and 3 times a day for 28 days. The remaining five patients (m1-m5) were given a dose of Tylenol 650mg 8 hours sustained release, a pain medication commonly prescribed for chronic plantar fasciitis.

After taking 28 days, pain was not felt even when moving, 5 points, pain was not felt when not moving, but pain was felt when moving, 3 points were given, and pain was felt even when not moving.

The measurement results were shown in Table 7 below.

EXAMPLES Taking Patients

<Comparative example> Taking patient

M1

M2
M3
M4
M5

m1
m2
m3
m4
m5
3

5
3
One
3
3
One
3
One
3

In the above measurement results, it can be seen that the pain improvement degree of the patient taking the pill according to the embodiment of the present invention is superior to the pain improvement degree of the patient taking the pill according to the comparative example.

Measurement of effects on periodontal disease

20 patients with persistent gingivitis over 1 year were divided into Group A and Group B. <Example> according to the present invention is to be taken once a packet of tid for 3 months, group B to <Comparative Example> dentamine capsule (ilyang drug), a gingivitis treatment on the market in the market 3 times a day 1 capsule After taking three months each, select one tooth with the highest degree of gingivitis and divide it into stenosis and cotton wool. 1 point for bleeding due to periodontal probe, severe inflammation, redness, edema, change of gingival color, 2 points for bleeding due to mild stimulation of periodontal probe, severe inflammation, redness, edema, ulcer In case of spontaneous bleeding, three points were evaluated, and the average grades were calculated after obtaining the index of gingival and lingual gingiva for each group of teeth before and after 1 month, 2 months, and 3 months after administration. The results are shown in Table 8 below.

Just before taking
(Mean ± standard deviation) 1 month after taking
(Mean ± standard deviation) 2 months after taking
(Mean ± standard deviation) 3 months after taking
(Mean ± standard deviation)
% Improvement
A group
Example


1.83 ± 0.31



1.71 ± 0.20


1.35 ± 0.21


0.89 ± 0.30


51.37%

B group
Comparative example
(Dentamine Capsule)



1.78 ± 0.38

1.70 ± 0.33


1.48 ± 0.38


1.35 ± 0.41


24.15%

The percent improvement was calculated by the following equation using the mean value immediately before taking the gingivitis index and the mean value after 3 months.

% Improvement = (gingivitis index immediately before dosing-gingivitis index 3 months after taking) / gingivitis index just before taking x 100

As can be seen in the above table, in both Examples and Comparative Examples, the gingivitis index tended to decrease as the duration of administration increased. However, the rate of change was greater in the Examples than in the Comparative Examples. In particular, the improvement rate after taking 3 months was confirmed that the embodiment of the present invention is almost twice or more than the comparative example.

<Measurement of effects on chronic cystitis>

1) Antiviral agent according to the present invention in 20 40-70 years old women diagnosed with chronic cystitis in the hospital, frequency of urinary frequency in the range of 10 to 16 times per day and nocturnal and urgency symptoms After taking 1 sachet 1 times 3 times a day to prepare a urination journal to evaluate the effect of the present invention.

As shown in Table 9, the daily average urination frequency, the average nocturnal urination frequency, and the daily average urine frequency were all significantly improved.

<For one bag three times a day>
Just before taking
3-day average

After 4 weeks
3-day average

After 8 weeks
3-day average
After 12 weeks
3-day average
Average urination frequency / day

14.2 times
12.1 times
11.0 times
9.8
Average night urination / day

3.2times
2.7times
2.2times
1.5times
Average urine frequency / day

2.9times
2.3times
2.1times
1.0times

2) Antiviral agent according to the present invention in 20 40-70 year-old women diagnosed with chronic cystitis in the hospital, the frequency of frequency of urinary frequency in the range of 12-18 times per day and nocturnal and urgency symptoms After taking two sachets three times a day once a urination journal was made to evaluate the effect of the present invention.

As shown in Table 10, the daily average urination count, the average nocturnal urination count, and the daily average urgency count were all significantly improved.

As a result of this clinical example, it was confirmed that the dose was increased in patients with relatively severe cystitis.

<Take 2 capsules 1 time 3 times a day>
Just before taking
3-day average

After 4 weeks
3-day average

After 8 weeks
3-day average
After 12 weeks
3-day average
Average urination frequency / day

15.8 times
13.0 times
10.9times
8.8 times
Average night urination / day

3.3times
2.5times
2.0times
1.5times
Average urine frequency / day

3.0times
2.3times
1.7times
0.8times

Measures of Effect on Hypertension

5 fasting systolic patients with fasting systolic / dilator blood pressure (M1) 155mmHg / 125mmHg, (M2) 149mmHg / 120mmHg, (M3) 164mmHg / 128mmHg, (M4) 158mmHg / 122mmHg, (M5) 148mmHg / 115mmHg The present invention is performed on 5 hypertensive female patients whose diastolic blood pressure is (W1) 152mmHg / 115mmHg, (W2) 148mmHg / 119mmHg, (W3) 165mmHg / 126mmHg, (W4) 157mmHg / 121mmHg, (W5) 149mmHg / 121mmHg, respectively. Antiviral drugs were taken by tid for 3 months, and fasting blood pressure was measured again after 3 months. The measurement results were (M1) 135mmHg / 95mmHg, (M2) 129mmHg / 98mmHg, (M3) 134mmHg / 90mmHg, (M4) 145mmHg / 111mmHg and (M5) 140mmHg / 100mmHg for 5 male patients, respectively. The light weights were (W1) 132 mm Hg / 85 mm Hg, (W2) 128 mm Hg / 90 mm Hg, (W3) 167 mm Hg / 130 mm Hg, (W4) 127 mm Hg / 89 mm Hg, and (W5) 139 mm Hg / 109 mm Hg. There were deviations in personal blood pressure drop in nine patients, but blood pressure dropped after taking as compared to before. In many patients with hypertension, viral infections have been shown to cause blood pressure by irritating certain areas of the body, such as blood vessel walls.

Measures of Effect on Diabetes

Diabetes with an average blood glucose level of 3 times measured on an 8-hour fasted state (P1) 134 mg / dl, (P2) 139 mg / dl, (P3) 132 mg / dl, (P4) 131 mg / dl, and (P5) 128 mg / dl Five patients with type 2 diabetes mellitus, each of the antiviral agents according to the present invention were administered with tid for 3 months and blood glucose measurement was performed. As a result, there were no significant changes in the mean blood glucose measured three times (P1) 133mg / dl, (P2) 139mg / dl, (P3) 130mg / dl, (P4) 132mg / dl and (P5) 125mg / dl, respectively. . In each patient, the antiviral agent according to the present invention was taken again with tid for 3 months and the diabetes test was performed 6 months after the first dose. P1) 120 mg / dl, (P2) 125 mg / dl, (P3) 119 mg / dl, (P4) 117 mg / dl and (P5) 124 mg / dl were obtained. The analysis resulted in about 10% hypoglycemia except one patient. Diabetes is expected to be a disease that raises blood sugar by inflaming the beta cells of the pancreas and the beta cells in the pancreas, and the result is that the beta cells in the pancreas to inflamed the virus that caused this result.

Clinical Cases for Individual Patients

[Clinical Study 1] Hepatitis B (50 years old, male)

A 50-year-old male patient was inflamed by the hepatitis B virus in the liver, complained of fatigue, and anemia. When infected, the body develops an immune response to remove it, which causes inflammation and fatigue in the liver as the infected liver cells are destroyed. In some cases, symptoms of anemia may occur. The patient was asked to take an antiviral agent according to an embodiment of the present invention 1 unit (4.8 g) three times three times a day for three weeks and liver function tests. As a result, the levels of GOT and GPT rose sharply, but they did not appeal to worsening symptoms or fatigue, and the anemia symptoms disappeared. The hepatitis B virus-infected hepatocytes are suddenly exposed to the antiviral agent of the present invention, and the virus-infected hepatocytes are also destroyed in the process of the virus eradication, and the GOT and GPT in the hepatocytes are released into the blood. Since then, for 11 months, the antiviral agent according to the embodiment of the present invention was appropriately added to and continuously taken. After 11 months, hepatitis B virus marker test was performed on this patient, and no hepatitis B virus surface antigen (s antigen) was detected.

[Clinical Trial 2] Herpes zoster (6 years old, female)

The inventor was a six year old girl whom she met in Beijing, who was suffering from herpes zoster. The girl had no symptoms when staying in Beijing strangely, but after two days of returning home. The antiviral agent according to an embodiment of the present invention was to be eaten twice a day for two months morning and evening for 0.5 units. He then returned home, with no herpes zoster rashes observed for two days, seven days, or ten days thereafter. Since then, shingles has not recurred have.

[Clinical Trial 3] Herpes zoster (male, 84 years old)

An 84-year-old man, who suffered from pain in his back, shoulders, and ribs after treating herpes zoster in dermatologists, was unable to sleep at night. Herpes zoster is a disease caused by the varicella-zoster virus herpes zoster in childhood and then reactivates. The virus that remains in the body travels along the nerves, lurks in the ganglions, and when the immune system weakens, painful inflammation occurs in the skin. The antiviral agent according to an embodiment of the present invention was taken two units (4.8 g x 2) twice a day for three days, and then one unit (4.8 g) three times a day for seven more days. The patient stated that after 10 days the pain had completely disappeared. Herpes zoster also had only some traces and no herpes was observed.

[Clinical Study 4] Herpes zoster (36 years old, male)

He is a 36 year old physique male. I have a herpes zoster and have come to buy painkillers because I can't sleep because of pain while taking prescription drugs. Instead of analgesic, the antiviral agent according to the embodiment of the present invention was to be taken three times a day, one unit once a day. The patient stated that after 3 days, herpes zoster traces remained and the pain completely disappeared. Thereafter, the same dose was further taken for 10 days to confirm visually that herpes completely disappeared. The antiviral agent according to the embodiment of the present invention was further taken for 4 months in order to completely eradicate the latent varicella-herpes zoster virus.

[Clinical Study 5] Herpes zoster (60 years old, female)

A few years ago, she suffered from herpes zoster for nearly a year. The same site is aching again and has been prescribed by the hospital for gabapentin, a herpes zoster antiviral. The antiviral agent according to the embodiment of the present invention was to be taken three times a day for 3 days by 2 units. The next day the pain disappeared immediately and said he would not take the prescription medicine. In order to completely remove the varicella-herpes zoster virus latent in neurons, an antiviral agent according to an embodiment of the present invention was further taken for 6 months.

[Clinical Trial 6] Influenza (63 Years, Male)

H1N1 was a symptom of Tamiflu in the hospital and was taken for a week. Since the improvement of symptoms caused by Tamiflu is insignificant, the antiviral agent according to the embodiment of the present invention was taken two times three times a day for one week. After a week, the improvement was noticeable, and the dose was taken three times a day for 1 week each. Two weeks later, the patient stated that symptoms of swine flu had disappeared completely.

[Clinical Trial 7] Influenza (56 years old, male)

He was an influenza patient with high fever and systemic pain caused by influenza B virus infection. The antiviral agent according to the embodiment of the present invention was to be taken three times a day for 3 days by 2 units. The patient stated that after three days the symptoms improved significantly. Thereafter, one unit was taken twice a day for 1 week. The patient stated that symptoms disappeared completely 10 days after starting the dose.

[Clinical Trial 8] Nose cold (45 years old, female)

It was a woman patient who usually suffered from a cold just once. He was infected with Rhinovirus. One unit of the antiviral agent according to the embodiment of the present invention was taken three times a day for 3 days. The patient stated that after three days the symptoms of cold disappeared completely.

[Clinical Trial 9] Nose cold (21 years old, female)

She was a female patient before the exam. I found a cold medicine that didn't make me sleepy. The antiviral agent according to the embodiment of the present invention was to be taken three times a day for 6 days one unit. I complained that my runny nose got worse after taking two days, but I kept taking it. The patient stated that from day 4, her nose was clear, her head was clear, and after 6 days, her cold symptoms disappeared completely.

[Clinical trial 10] Mokgigi (48 years old, male)

A male patient with a throat wound. The patient was infected with adenovirus. The antiviral agent according to the embodiment of the present invention was taken once a day for 3 days twice a day, but the cold symptoms did not improve because the air conditioner worked in a low temperature office. The antiviral agent according to the embodiment of the present invention was increased three times a day by 2 units to be taken for 3 more days. The patient stated that after three days the symptoms of a sore throat disappeared.

[Clinical trial 11] Mokgigi (40 years old, female)

She was a 40-year-old woman who lived day and night. The patient was infected with adenovirus. The patient was admitted to the hospital several times with continued throating, and he was continually hit by Ringer every time he came to the hospital. The antiviral agent according to the embodiment of the present invention was to be taken three times a day three times a day. The patient stated that day 2 was much easier to wake up in the morning, the symptoms of cold were much better, and the symptoms of cold disappeared completely in a week.

[Clinical trial 12] Chronic phlegm (73 years old, male)

The 73-year-old man has been bathing for more than three years in a hospital prescription because his phlegm keeps boiling. The antiviral agent according to the embodiment of the present invention was to be taken once a day for 7 days three times a day. As a result, the amount of sputum was significantly reduced. The patient was asked to take 1 additional unit twice a day for 3 months. After three months of additional dosing, the patient stated that no more phlegm developed. Chronic diseases occurring in the mucous membranes are most likely to be viral diseases, and the result is prescribed.

Clinical Trial 13 Psoriasis (38 years old, male)

The patient began skin lesions eight years ago and has been diagnosed with psoriasis in the hospital and treated continuously. Erythematous skin lesions, characteristic of psoriasis, were evenly visible on the entire skin. Initially, the antiviral agent according to the embodiment of the present invention was taken three times a day for three months. After 1-2 weeks of administration, the skin lesions all over the body, and after 12 weeks, it improved a lot. Six months later, no drooping or erythema was observed visually. Psoriasis is a erythematous skin lesion that is covered with a clear border of silver-white scales and is a representative chronic skin disease that is likely to be repeated once in a lifetime and the cause is not clear.

Clinical Trial 14 Psoriasis (31 years old, female)

Psoriasis was diagnosed in every hospital where skin lesions started 20 years before administration with an antiviral agent according to an embodiment of the present invention. Erythematous skin lesions, characteristic of psoriasis, were evenly visible on the entire skin. The antiviral agent according to the embodiment of the present invention was taken for 3 months while appropriately adjusting the dose. Symptoms aggravated within 1 to 2 weeks of treatment, skin lesions began to fill the entire body, and after 3-4 weeks, erythema and scale were gradually disappeared. As a result of taking the antiviral agent according to the embodiment of the present invention for 24 months while appropriately adding or subtracting the dose, erythema or sulcus was no longer visually observed on the skin. It was determined that the antiviral agent according to an embodiment of the present invention was thought to be a result of removing all viruses that cause psoriasis.

Clinical Trial 15 Psoriasis (55 years old, male)

For many years, every haircut has been pointed out by a barber to spread the borderline erythematous skin lesions covered by the scale from the back scalp to the back neck border. Determined by psoriasis, the antiviral agent according to the embodiment of the present invention was to be taken twice a day for 1 month. After one month the borderline was markedly reduced. After one month, the amount was increased to take an antiviral agent according to an embodiment of the present invention one unit three times a day for three months. After three months, the erythema disappeared almost indistinguishable from the surrounding skin color. In order to cure psoriasis-causing virus, the antiviral agent according to the embodiment of the present invention was taken once a further unit twice a day for 3 months.

[Clinical Trial 16] Atopic dermatitis (36 years old, male)

He had atopic dermatitis from a young age, but he had no symptoms. He began to have symptoms on his forehead, wrist, and back neck for three years. Atopic dermatitis was diagnosed in the hospital. The skin is severely itchy, dry and pulled, severe areas are cracked and bleeding so bad that you can't sleep, so every two days you get warm water in the bathtub and let the hot water come out a little bit to keep it cool. I slept. The atopy's severe job had already retired. Two units of antiviral agent according to an embodiment of the present invention were taken three times a day for the first two months, and then, one unit of three times a day for an additional seven months. The symptoms seemed to worsen between 7-14 days after the first dose, but treatment continued without interruption. Nine months later, atopy symptoms could not be observed in the skin of the patient, and the patient no longer felt itchy.

[Clinical Study 17] Atopic dermatitis (48 years old, male)

This man had a severe dermatitis on the face. The patient took antihistamines and immunosuppressants prescribed by a dermatologist but did not improve symptoms. The patient with red swollen face was given an antiviral agent according to an embodiment of the present invention two units three times a day for 7 days. After seven days, the red, swollen skin was soothing and the color returned to normal. After confirming the above effects, the antiviral agent according to an embodiment of the present invention was to be taken three times a day for 6 months once a day. After starting the application of the present invention, the symptoms of atopic dermatitis with red swelling of the face did not occur anymore, and after six months, it was confirmed visually that other symptoms of atopic dermatitis disappeared.

[Clinical Trial 18] atopic dermatitis (17 years old, female)

She was a 17-year-old high school girl who had atopic dermatitis in her knees and thighs. The antiviral agent according to the embodiment of the present invention was to be taken two times for 14 days three times a day. Initially, symptoms worsened as expected and gradually improved. Thereafter, in order to cure the virus causing atopic dermatitis, the antiviral agent according to the embodiment of the present invention was taken once more for 6 months twice a day. After six months, no symptoms of atopic dermatitis were observed in the knees and thighs, as well as in other areas.

[Clinical Trial 19] Vitiligo (34 Years, Male)

This patient had severe symptoms of vitiligo, especially in the face, hands, and wrists, and evenly spread across the body. Especially, the eyelashes of the eyelids with vitiligo developed were white. The antiviral agent according to the embodiment of the present invention was appropriately added to and taken for 24 months. Twenty-four months later, visual observation revealed that the symptoms of vitiligo (white spots) mostly disappeared from the skin, but the white eyebrows remained intact. Vitiligo is an acquired depigmentation disease of which white spots of various sizes appear on the skin due to the destruction of melanocytes, although the exact cause is not known. There are also several ways to treat it, but it is a difficult disease to treat completely. If you look at the symptoms of vitiligo, the skin around the bleached white spots are rather melanin secretion is black than normal skin. Although not a form of typical viral inflammation, it has been estimated that melanocytes are a skin disease caused by a virus susceptible to melanocytes. When melanocytes die from viral infection, they can't secrete melanin pigment and cause vitiligo, but until it dies, it is believed that the skin is blackened by secreting more melanin pigment due to inflammatory stimulus. Therefore, the healing process of vitiligo is to eradicate the virus that is the cause first. Afterwards, the skin environment is created and maintained to allow melanocytes to settle. Then, at the end of the healing process, white spots become normal skin color, and at the same time, the surrounding dark skin returns to skin color and heals. The treatment of vitiligo requires 12-24 months of long experience, and the improvement does not appear early, but begins to appear almost at the end of healing.

[Clinical trial 20] Chronic rhinitis (40 years old, female)

A 40-year-old woman with chronic rhinitis always swollen the mucous membrane of his nose, so it was hard to sleep if you do not turn on the humidifier when you sleep. The antiviral agent according to an embodiment of the present invention was taken twice a day for 12 weeks, one unit each. At 3 weeks, breathing became easier, the nasal mucosa was noticeably diminished, the nose began to feel much relaxed, and after 12 weeks the patient stated that she no longer felt previous chronic rhinitis. The sinuses and airways are areas that come in contact with the outside air and are easily exposed to viruses and bacteria. Diseases caused by bacterial infections improve with the development of antibiotics and rarely progress to chronic diseases except tuberculosis. However, when the virus is infected, the development of antiviral agents capable of killing the virus is insignificant, so proper treatment cannot be achieved, causing diseases such as chronic rhinitis, asthma, and tonsils. At this time, taking an antiviral agent according to an embodiment of the present invention, the inflammation is reduced by removing the virus causing inflammation due to the infection of the sinuses or the airways, thereby improving chronic rhinitis, asthma, enlarged tonsils and the like.

[Clinical Trial 21] Sore throat (60 years old, female)

The patient had a discomfort and painful condition that lasted for more than six months, as if the neck was still tightened and caught. There were no neck bumps or tests, and there was no drive after two months of treatment for otolaryngology. Therefore, the antiviral agent according to the embodiment of the present invention was to be taken three times a day for 7 days each 1 unit. After seven days, the patient stated that the discomfort in the neck had disappeared and she was able to sleep well. It was very likely that it was a viral infection of the throat mucosa.

[Clinical trial 22] Chronic gastritis (54 years old, female)

This patient is a female pharmacist who suffered from indigestion and congestion due to chronic gastritis. The antiviral agent according to the embodiment of the present invention was to take 1 unit twice a day for 4 weeks. The patient stated that after two weeks of ingestion, the symptoms of indigestion after eating disappeared and no longer eat and prey. The gastric mucosa is a site where food enters directly from the outside and, like the nasal mucosa and airways, is vulnerable to invasion of the virus. Therefore, if gastrointestinal diseases such as gastric atony, chronic gastritis, and gastric ulcers continue to be cured repeatedly without treatment, the virus-infectious disease needs to be suspected. Chronic gastritis and gastric ulcers, which are not improved by gastric acid secretion inhibitors and antibiotics, and gastric atony, which are not improved as well as gastrointestinal motility regulators, can be used. A number of clinical cases were obtained.

[Clinical Trial 23] Allergy (55 months, male)

The patient was a 55-month-old boy. Since birth, he has suffered a lot of food allergy (apple shells, peaches, plums, fruits, shrimps, shellfish, shellfish, eggs, nuts, etc.). Appeared frequently. In addition, allergic runny nose rhinitis persisted and caught a cold, the eye did not heal well, and the eye was always congested due to allergy (allergy) conjunctivitis. The antiviral agent according to the embodiment of the present invention was changed into a blender by 1 unit and then taken twice a day for 4 weeks after being combined with yogurt. After three days of eating, the irritated yellowish runny nose turned into a clear runny nose, and it was less tickling and the eyes were not rubbed. Currently, allergy is known as a viral disease.

[Clinical Trial 24] fibromyalgia (59 years old, female)

The patient was a chronic pain patient who complained of pain, tingling and numbness in the lower back, shoulders, arms, and legs and no sore body. In the evening, it was hard, so it became pa Kimchi. The antiviral agent according to the embodiment of the present invention was to take 1 unit twice a day for 4 weeks. The patient stated that on the third day of taking, the body became lighter and the pain began to disappear, and at some point there was no place to eat or sore. The patient suspected that various parts of the body were infected with the virus.

[Clinical Study 25] Chronic Finger Pain (58 Years, Male)

One month ago, the first thumb of the right thumb was bitten by the person, and the suture treatment was continued. There was no purulent pain, and there was severe pain in the wrist and shoulder. Eight years ago, the same site was bitten by the same person and 80 stitches were treated. It is determined that it is a viral infection that continues to be ill for one month but does not have a purulent infection, so that the antiviral agent according to the embodiment of the present invention is taken twice a day for 4 weeks. The patient stated that after 4 weeks the pain and myalgia had cleared. After the pain and myalgia disappeared, the same dose was taken for 5 months to cure the virus.

[Clinical Trial 26] Hypertension (53 years old, male)

The patient, a 53-year-old male, usually has high blood pressure and complains that taking blood pressure medications causes her blood pressure to drop so unstablely and dizzy. The patient was allowed to take an antiviral agent according to the present invention 1 unit twice a day for 3 months. After 3 months, the measured blood pressure was steadily dropped to around 121 mmHg of systolic blood pressure and 81 mmHg of diastolic blood pressure without taking blood pressure medicine. Hypertension is a typical lifestyle disease caused by irritating food, obesity, lack of exercise, and excessive stress. Although the inventors did not think of hypertension as a viral disease at first, this clinical case in which blood pressure was controlled by taking an antiviral agent according to the present invention can raise blood pressure by causing a viral infection to cause inflammation in a specific part of the body. It was judged that there was.

[Clinical Trial 27] Type 1 Diabetes (42 Years, Female)

This patient had severe foot pain due to severe diabetes. When I woke up every morning, it was so bad that I pierced my soles with dozens of needles, so I couldn't step on the floor, sit on the bed and rub it for an hour or more to walk. Diabetes in this patient was type 1 diabetes developed after severe acute pancreatitis. At the time, the insulin was injected in the morning and evening, the blood sugar level did not drop below 200 mg / dL, and the blood sugar level was higher for 2 hours after eating. The thirst was so severe that the tongue was cracked and the cold water wasn't cool enough to quench thirst if the beer had been frozen in the freezer before drinking or chewing ice. The patient was not allowed to drink cold water, only water warmer than body temperature, and spicy foods were forbidden. After one week of control, so much thirst was gone and blood sugar began to stabilize. This means that cold stimulation causes the sympathetic excitement to break out of the vicious cycle that continues to raise blood sugar and cause thirst. Then, the antiviral agent according to the embodiment of the present invention was appropriately taken (two units twice a day for three months), and the insulin injection amount was reduced to 5 units only for morning. The patient stated that the pain of the foot disappeared in the course of taking the antiviral agent according to the embodiment of the present invention, and the inflammation of the foot was gradually reduced. Through this patient, even type 1 diabetes was able to reduce insulin injections and improve symptoms. This was determined to be due to the eradication of the virus causing inflammation of the beta cells of the pancreas with an antiviral agent according to an embodiment of the present invention. The reduced insulin dose is considered evidence of the renewal and activity of the pancreatic beta cells. Diabetes, like hypertension, is a typical lifestyle disease caused by irritating food, obesity, lack of exercise, excessive stress, etc. Although the inventors did not think of diabetes as a viral disease at first, the present invention experienced a clinical case in which blood glucose was controlled by taking an antiviral agent according to an embodiment of the present invention. It was determined that the disease raises blood sugar.

[Clinical Trial 28] Infertility (31 years old, female)

This patient In order to treat infertility, he took a year off to work and wanted in earnest treatment. However, in reality, her physical strength was so weak that even light daily life was difficult, and she was eager to strengthen her health rather than want to become pregnant. In case of female infertility, if there is no special cause due to the diagnosis of obstetrics and gynecology, female genitals are severely inflamed due to viral infections, which prevents pregnancy, and therefore, there is a lack of extra stamina to maintain pregnancy. Therefore, he recommended a cure that eliminated the virus, helped him gain enough strength, and help her become pregnant, and the patient accepted it. He said that he had severe menstrual cramps in his physical condition, his belly was cold, and his uterus was not clean by ultrasound. Contraception was recommended, and after taking the antiviral agent according to the embodiment of the present invention for a total of 12 months while adjusting the amount, it was recommended to try pregnancy after 12 months. In the same week, she gave birth to her first child without any problems and then to her second child after 22 months without additional care.

[Clinical Trial 29] Virus Progressive Brain Lesion Disorder (9 years old, male)

Suddenly, he had a high fever and was diagnosed with a progressive brain lesion caused by a virus at Samsung Medical Center. Symptoms were accompanied by a decrease in cognitive and motor skills, and occasionally a seizure. The patient's mother was a trusted caregiver with experience in helping the inventors heal atopic dermatitis for over 20 years. Since the patient has already been diagnosed with a brain disease caused by a virus, an antiviral agent according to an embodiment of the present invention is appropriately taken for 24 months to eliminate the virus. In the meantime, the epilepsy that had been taken was cut off, and the epilepsy did not occur, and the intelligence and exercise ability were restored to normal. At the 23rd month, regular brain scans conducted by Samsung Medical Center confirmed that the virus infection area, which had previously been seen, was no longer present.

[Clinical trial 30] Brain lesion disorder (7 years old, female)

This patient is a girl diagnosed with intellectual disability level 2. Intellectual disorder was reported as a viral brain lesion disorder of the central nervous system, and the antiviral agent according to the embodiment of the present invention was taken for 24 months with or without a dose. At first, they could not walk properly and had to hold their hands around them, they could not speak, and they could not communicate or communicate with each other. Currently, he runs and collects his hair and runs, and he is growing up to be a normal child. In this case, it is determined that the virus causing inflammation of the central nervous system by the antiviral agent according to the embodiment of the present invention is killed. In addition to intellectual disorders, neurological disorders such as developmental disorders, developmental delays, depression, ADHD (attention deficit hyperactivity disorder), insomnia, panic disorders, and obsessive-compulsive disorders, such as obsessive-compulsive disorder, are not likely to be identified. However, as with viral brain lesions, the virus invades the central nervous system and damages part of the brain nerve or prevents it from functioning. Regardless of disease or symptoms, the cause is all due to virus-induced central neuritis, so all the necessary prescriptions are the same. In addition, it was confirmed through various clinical cases that the younger the infection, the more severe the symptoms and the longer the change in appearance, the longer the healing period.

[Clinical Trial 31] Developmental Disorders (4 years old, male)

She was managed by the Pediatric Mental Health Development Clinic at Seoul Medical Center. The results of psychological education test conducted by Seoul Medical Center were actual age-3 years 2 months, living age-16 months, and developmental index (DQ)-42.1. For reference, the development index (DQ) is similar to IQ, 100 is the standard, if more than 100 development is ahead, if less than 100 can be seen as late. In addition, they showed difficulty in carrying out tasks in a structured environment, such as following language directions and sitting, and were limited in performing items that required to imitate others' language and actions or that required challenge or repetition. The patient was administered an antiviral agent according to an embodiment of the present invention for about 24 months with appropriate dose reduction. As a result, the psychological education test progress report showed a significant improvement to the actual age-4 years 5 months, the living age-4 years 1 month, and the developmental index (DQ)-92.5. In addition, you can stay seated for a certain period of time, focusing on tasks, and improving your basic social skills, perception, small muscles, large muscles, hand-eye coordination, and behavioral and linguistic cognition required for interaction with others such as imitation and language expression. He also showed progress in basic learning techniques such as attention, scissoring, drawing lines and shapes, and the interest and utilization of materials and toys.

[Clinical trial 32] Muscular Dystrophy (5 years old, male)

He is a Chinese boy living in Beijing who has been diagnosed with Muscular Dystrophy and has been around the country for more than half a year, looking for the possibility of treatment, but in desperation. Prior to healing by the antiviral agent according to the embodiment of the present invention, the developmental state was sluggish and barely walked about 30-50 meters. In order to go up the bed, there was no strength in the hands, so he could not climb his hands and climbed his head against the bed. It is a case where the child is accompanied by a decrease in intelligence because he did not sit in kindergarten and did not participate in the class and played with other children. When I touched my legs, I didn't have any flesh under my knees, so I only felt bones, and some muscles in my calf were solid like stones, and my hip muscles were slightly hardened. He was 82 centimeters shorter than the other children. For 7 months, the antiviral agent according to the embodiment of the present invention was taken with or without a dose. After seven months, they can walk for several ten minutes, grab their parents' hands, run lightly, run their assorted feet, climb their hands on the bed, sit well in class in kindergarten, participate in class, or hang out with children. Legs have normal hip muscles and calves have many muscles, which are not much different from normal people. In addition, many of the hard touches like stones under the calf muscles have been released, but they are not yet normal. Miraculously, before taking the antiviral agent according to the embodiment of the present invention, the height was 82 centimeters, which was much shorter than his peers, but increased to 109 centimeters by 27 centimeters in only seven months, rather than other children. This is about a third of her height, and the clumps of legs interfered with the growth of the bones, and the muscles were released and the state of health improved. Muscular Dystrophy is a hereditary and progressive myopathy that has been known to show progressive muscle atrophy and muscle weakness, and there are no specific treatments to date. Depending on the type, it starts from early childhood to adulthood and progresses with age, making walking difficult, resulting in curvature of the spine, difficulty in breathing, and abnormal pneumonia or sepsis associated with bed rest due to myocardial abnormalities. He may die from his back. However, in 20% of cases, such as facial shoulder brachial muscle regression axis, the disease develops relatively late and progresses slowly. In addition, the intelligence index may decrease depending on the type, and death is caused by respiratory failure due to respiratory muscles or myocardial involvement. However, while managing patients with Muscular Dystrophy, he confirmed that the patient's condition was definitely improved and decided that it was a treatable and viral disease.

[Clinical trial 33] Cri du chat syndrome (5 years old, female)

Cri du chat syndrome is a congenital disorder caused by chromosomal abnormalities that cause crying similar to cat crying. Cri du chat syndrome was first reported in 1963 and appears because part of the fifth chromosome is cut off, resulting in dysplasia and incomplete laryngeal development. Characteristic symptoms include crying similar to cat crying, microcephaly, and intellectual disability. Other symptoms include a round face, wide glans, work experience, palm deformity, flat foot, and short neck. About 20% have congenital heart disease. As you grow older, you may gradually lose your cat's crying, work experience, and round face, and there are no special treatments yet. This patient was not in communication with the antiviral agent according to the embodiment of the present invention at all, was unable to get along with others, and was separated separately. For 24 months, the antiviral agent according to the embodiment of the present invention was taken while appropriately decreasing the dose. After starting taking, my development improved, and after 24 months I was much taller than my brother and weighed so much that I couldn't wear the same size clothes. Also, if you ask me to take a picture, it will pose and it will suit you better than before. In this case, it is also improved by prescriptions such as brain lesion disorder, developmental disorder, and developmental delay, which are supposed to be viral central neuritis. From this, it was confirmed that Cri du chat syndrome is a treatable disease and also a viral disease.

[Clinical Trial 34] Down's syndrome (12 years old, female)

Down's syndrome is a representative genetic disease that causes mental retardation, body malformation, systemic dysfunction, and growth disorder due to the presence of three chromosomes 21, two of which are normal. It is characterized by a combination of characteristic facial deformities such as a small head, a round and flat face with a low nose, an elevated eye tail, and a distance between both eyes. The neck looks short and thick, and there is no muscle strength. It is late in development, so it takes two years to walk, and it is too late to grow into an adult, and the average intelligence is about 20-50. They do not grow well, so they are short in adulthood and are often observed as obese. This patient was a patient who applied the antiviral agent according to the embodiment of the present invention for two years to confirm whether the antiviral agent according to the embodiment of the present invention can cure Down's syndrome. Before applying the antiviral agent according to an embodiment of the present invention is a typical Down's syndrome (intelligence), the intelligence level is not enough to talk about the current grade and half of last year, but children with a lot of cognitive ability to talk about last year and half It was. While taking the antiviral agent according to the embodiment of the present invention for 24 months while appropriately adding or subtracting the dose, it was confirmed that the appearance was improved only 4 months after the start of the administration. One of the characteristics of Down's syndrome is that the forehead, nose, and lips are in a straight line. As the jaw enters, the forehead, nose, and lips are not in a straight line. The jaw was pushed out due to cerebral edema, which is thought to have returned to normal as the brain edema decreased. In the process, the shoulders and neckline were reduced, and at the same time, the fingers grew specially. This is thought to change as the blood gathered in the shoulders and head goes down to the limbs. The fingers of Down's syndrome patients are short, and the fingertips become thinner and thinner. The growth of the fingers showed that the fingertips swelled like the frog's feet and gradually became the same thickness. After 24 months, the intelligence level developed so much that she was able to talk to her grandmother who was her guardian and nag. It was concluded that Down's syndrome caused viral central neuritis and caused various physical changes.

<Effect tracking result for manufactured goods>

Applicant sells the antiviral drug ring according to an embodiment of the present invention through a pharmacy. The follow-up of patients who were administered by pharmacists who participated in sales confirmed the following symptoms.

1) The results of follow-up on 1,000 influenza patients were found to improve symptoms in 925 patients (92.5%).

2) The results of the administration of 500 rhinovirus patients were followed for improvement of symptoms in 453 patients (90.6%).

3) The results of follow up of 100 patients with herpes zoster confirmed the improvement of symptoms in 91 patients (91%).

4) The results of follow-up of 100 atopic dermatitis patients were found to improve the symptoms in 88 patients (88%).

5) The results of follow-up of 300 chronic rhinitis patients showed improvement of symptoms in 243 patients (81%).

6) The results of follow up of 100 psoriasis patients showed improvement of symptoms in 79 patients (79%).

6) The results of follow-up of 100 hypertensive patients were found to improve symptoms in 69 patients (69%).

6) Follow-up results were administered to 100 chronic cystitis patients and 55 patients (55%) showed improvement of symptoms.

6) The results of follow-up of 100 patients with periodontal disease confirmed the improvement of symptoms in 85 patients (85%).

6) The results of follow up of 100 patients with chronic fascia disease showed improvement in symptoms in 43 patients (43%).

Claims (1)

Maple Syrup 1-30%, Bamboo 1-30%, Uyiin 5-60%, Xylitol 10-40%, Vitamin C 1-20%, Manuka Honey 1-20%, Frankincense 1-20% An antiviral agent for the treatment or alleviation of influenza A virus comprising%, 1-20% by weight, and 0.1-10% by weight of propolis, in powder, liquid or extract form.